167 related articles for article (PubMed ID: 1643698)
21. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
23. [Phase I study of 5-fluorouracil and l-leucovorin].
Sasaki T; Ota K; Wakui A; Akazawa S; Ogawa M; Ariyoshi Y; Yura J; Inagaki J; Hoshino A; Abe T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):485-91. PubMed ID: 8452386
[TBL] [Abstract][Full Text] [Related]
24. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
Grem JL; Yee LK; Schuler B; Hamilton JM; Chen AP; Chabuk C; Grollman F; Grabenc M; Allegra CJ; Takimoto CH
Ann Oncol; 2001 Nov; 12(11):1581-7. PubMed ID: 11822758
[TBL] [Abstract][Full Text] [Related]
25. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
28. A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
Eder JP; Garcia-Carbonero R; Clark JW; Supko JG; Puchalski TA; Ryan DP; Deluca P; Wozniak A; Campbell A; Rothermel J; LoRusso P
Invest New Drugs; 2004 Apr; 22(2):139-50. PubMed ID: 14739662
[TBL] [Abstract][Full Text] [Related]
29. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
Chi KH; Chan WK; Shu CH; Law CK; Chen SY; Yen SH; Chen KY
Cancer; 1995 Dec; 76(11):2186-92. PubMed ID: 8635020
[TBL] [Abstract][Full Text] [Related]
30. Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group.
Patel R; Newman EM; Villacorte DG; Sato JK; Reaman GH; Finklestein JZ; Krailo MD; Hammond GD; Holcenberg JS
Cancer Res; 1991 Sep; 51(18):4871-5. PubMed ID: 1893377
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
32. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
Scheithauer W; Depisch D; Kornek G; Pidlich J; Rosen H; Karall M; Prochaska M; Ernst A; Sebesta C; Eckhardt S
Cancer; 1994 Mar; 73(6):1562-8. PubMed ID: 8156482
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Stridhar K; Reddy R; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Livingstone A
Int J Radiat Oncol Biol Phys; 1992; 22(3):511-4. PubMed ID: 1735689
[TBL] [Abstract][Full Text] [Related]
34. Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.
Sobrero AF; Aschele C; Guglielmi AP; Mori AM; Tixi LM; Bolli EA; Rosso R; Mammoliti S; Rollandi GA; Bertoglio S
Clin Cancer Res; 1995 Sep; 1(9):955-60. PubMed ID: 9816066
[TBL] [Abstract][Full Text] [Related]
35. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
Yeh KH; Lu YS; Hsu CH; Lin JF; Hsu C; Kuo SH; Li SJ; Cheng AL
Oncology; 2005; 69(1):88-95. PubMed ID: 16088236
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
Cao S; Troutt AB; Rustum YM
Cancer Res; 1998 Apr; 58(8):1695-9. PubMed ID: 9563485
[TBL] [Abstract][Full Text] [Related]
39. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Doroshow JH; Multhauf P; Leong L; Margolin K; Litchfield T; Akman S; Carr B; Bertrand M; Goldberg D; Blayney D
J Clin Oncol; 1990 Mar; 8(3):491-501. PubMed ID: 2407810
[TBL] [Abstract][Full Text] [Related]
40. A phase I-II study of 14-days continuous infusion of 5-fluorouracil with weekly bolus leucovorin in metastatic colorectal carcinoma.
Sinnige HA; Nanninga AG; Verschueren RC; Sleijfer DT; de Vries GE; Willemse PH; Mulder NH
Eur J Cancer; 1992; 28A(4-5):885-8. PubMed ID: 1524916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
